Gaurav D. Shah
Chief Executive Officer at ROCKET PHARMACEUTICALS, INC.
Net worth: 28 M $ as of 2024-03-30
Profile
Gaurav D.
Shah is currently the Chief Executive Officer & Director at Rocket Pharmaceuticals, Inc., the President, Chief Executive Officer & Director at Rocket Pharmaceuticals Ltd., and the Chairman at Anjarium Biosciences AG.
Previously, he worked as a Medical Director at Eli Lilly & Co., an Independent Director at Talaris Therapeutics, Inc., the Head-Global Clinical Program at Novartis Corp., and an Assistant Professor-Oncology at The Trustees of Columbia University in The City of New York.
He holds a doctorate degree from The Trustees of Columbia University in The City of New York and an undergraduate degree from Harvard College.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-02-15 | 1,027,577 ( 1.14% ) | 28 M $ | 2024-03-30 | |
-.--% | 2023-06-12 | 0 ( -.--% ) | - $ | 2024-03-30 |
Gaurav D. Shah active positions
| Companies | Position | Start |
|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Chief Executive Officer | 2018-01-03 |
Rocket Pharmaceuticals Ltd.
 Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Chief Executive Officer | 2015-08-31 |
Anjarium Biosciences AG
 Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | Chairman | 2022-10-17 |
Former positions of Gaurav D. Shah
| Companies | Position | End |
|---|---|---|
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Corporate Officer/Principal | 2015-08-31 |
| The Trustees of Columbia University in The City of New York | Corporate Officer/Principal | 2011-11-30 |
| ELI LILLY AND COMPANY | Chief Tech/Sci/R&D Officer | 2010-12-31 |
| TOURMALINE BIO, INC. | Director/Board Member | - |
Training of Gaurav D. Shah
| The Trustees of Columbia University in The City of New York | Doctorate Degree |
| Harvard College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| ROCKET PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
Talaris Therapeutics, Inc.
 Talaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company, which engages in the development of allogeneic hematopoietic stem cell transplantation. The company was founded by Suzanne Ildstad on February 15, 2002 and is headquartered in Wellesley, MA. | Health Technology |
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Health Technology |
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | Health Technology |
- Stock Market
- Insiders
- Gaurav D. Shah
